The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Boston Scientific (BSX) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.50 per share a year ago.

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast ...

[Image courtesy of Boston ... with cost-effective tools developed specifically and uniquely for the Farapulse PFA system,” said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific.

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Boston Scientific (NYSE: BSX) + today reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance again. The company’s CEO also said on its third ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...